Senescent cells, senolytics and tissue repair: the devil may be in the dosing

Khosla, Sundeep

doi:10.1038/s43587-023-00365-6

Javascript is disabled or not supported in your browser. JavaScript must be enabled in order for you to use WIKINDX fully. Enable JavaScript through your browser options then try again, otherwise, try using a different browser.

BioAcyl Corp

WIKINDX Resources

Khosla, S. (2023). Senescent cells, senolytics and tissue repair: The devil may be in the dosing. Nature aging, 3(2), 139–141.
Added by: Dr. Enrique Feoli (18/05/2023, 15:32) Last edited by: Dr. Enrique Feoli (18/05/2023, 15:32)

Resource type: Journal Article
DOI: 10.1038/s43587-023-00365-6
ID no. (ISBN etc.): 2662-8465
BibTeX citation key: Khosla2023
View all bibliographic details

Categories: BioAcyl Corp
Subcategories: Stemness
Creators: Khosla
Collection: Nature aging

Views: 1/147

Abstract

There is tremendous interest in the development of drugs that target senescent cells (‘senolytic’ drugs) to treat a range of age-related morbidities. However, studies in mice that demonstrate impaired tissue repair following clearance of senescent cells raise questions about the potential risks of senolytic therapies. Closer examination of the available studies reveals the hopeful possibility of a ‘therapeutic window’ in which these risks can be minimized.